Tagged with Switzerland

Switzerland Pharmaceutical manufacturing is evolving into a strategic pillar of competitiveness, shaped by modular design, digital integration, and a growing focus on long-term efficiency. Bilfinger, through its Technology segment, is playing a central role in this transformation, supporting clients across biopharma, energy transition, and nuclear with scalable, future-ready solutions. In this…

Global Whether in the corridors of the FDA or the fast-evolving frameworks of ANVISA in Brazil, regulators around the world are undergoing a quiet revolution. While mature markets like the US and Europe double down on digitalisation and real-world evidence, emerging players like Brazil and China are accelerating access and joining…

Global As the global population ages and the incidence of vision-related conditions rises, ophthalmology is entering a transformative era. Beyond symptom management, the field is moving towards disease modification through cell and gene therapies like optogenetics while boosting artificial intelligence (AI) to speed up pipelines, and developing minimally invasive delivery systems…

Switzerland Urs Indermühle sees 2025 shaped by three big shifts and two urgent risks: R&D is now mostly sourced externally (just 35 percent developed in‑house), forcing pharma to master licensing and ecosystem partnerships; Asia, especially China, has become a serious innovation hub, making global IP and footprint strategies a priority; and…

Europe Pharma and biotech companies are doubling down on innovation and, often, outsourcing just about everything else. That shift has turned contract development and manufacturing organisations (CDMOs) into critical partners, not just service providers. The sector is booming, but pressure is building fast: demand is surging, capacity is stretched, and new…

Switzerland Tomaso Dameno, CEO of Primex, brings over 20 years of pharmaceutical experience across manufacturing, consulting, commercial operations and strategic leadership. After roles in the industry and leading international consulting initiatives, he joined Primex in 2018 as COO. Now at the helm following former CEO Alan’s Knox’s retirement, he is guiding…

Switzerland Doetsch Grether may be 126 years old, but it is anything but traditional. With a portfolio that spans pharmaceuticals, consumer health, and retail – an uncommon mix for a company of its size – the Swiss firm is doubling down on focused expansion, values-driven culture, and long-term partnerships. For Wannhoff,…

Switzerland Riad Sherif, CEO of Oculis, leads strategic innovation in ophthalmology and neuro-ophthalmology. With over 25 years of global experience, he has built a highly differentiated late-stage pipeline focused on addressing unmet medical needs through visionary innovations. Under his leadership, Oculis has grown from a hospital project with a single asset…

Switzerland In a milestone for global health, Novartis has received Swissmedic approval for Coartem Baby, the world’s first antimalarial treatment tailored for newborns and infants under 4.5kg. The decision fills a long-standing therapeutic gap and reinforces the company’s commitment to diseases that fall outside the pharmaceutical industry’s traditional commercial priorities.  …

Switzerland Prof. Andrea Alimonti, Director of the Institute of Oncology Research in Bellinzona, a leading Swiss centre focused on translational cancer research, shares his international journey from Rome to New York , Boston, and now Ticino, where he leads a growing, high-impact research institute. Under his leadership, IOR is expanding with…

Europe For over two decades, Europe’s pharmaceutical manufacturing footprint has steadily shifted offshore towards countries like China and India, driven by the pursuit of lower costs and operational efficiencies. However, the COVID-19 pandemic, coupled with growing geopolitical instability and increasing complexity in modern therapies, has exposed the risks of this model.…

Switzerland Over the past decade, Dr Lutz Hegemann has helped transform Novartis’ Global Health unit into a strategic pillar that bridges innovation with real-world access. Rather than focusing on visibility, the mandate centres on sustainable impact; embedding access into R&D, rethinking the value of established medicines, and advocating for systemic change…